DOCSLIB.ORG

Everolimus > Printer-Friendly PDF

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Everolimus > Printer-Friendly PDF Published on British Columbia Drug and Poison Information Centre (BC DPIC) ( http://www.dpic.org) Home > Drug Product Listings > Everolimus > Printer-friendly PDF Everolimus Trade Name: Afinitor Manufacturer/Distributor: Novartis 1-800-363-8883 or [email protected] Classification: Antineoplastic agent ATC Class: L04AA18 Everolimus Status: active Notice of Compliance (yyyy/mm/dd): 2009/12/14 Date Marketed in Canada (yyyy/mm/dd): 2010/02/12 Presentation: Tablets: 5 mg; DIN: 02339501 Tablets: 10 mg; DIN: 02339528 Comments: For treatment of metastatic renal cell carcinoma of clear cell morphology, after failure of initial treatment with either sunitnib or sorafenib. Access: public Back to: Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database Status: <Any> ? Search Terms: Apply A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4) Date Marketed in Common Generic Name Classification Canada Trade Name(s) (yyyy/mm/dd) Semaglutide Ozempic Incretin mimetic 2018/02/22 Semaglutide Rybelsus Incretin mimetic 2020/04/19 Sibutramine Meridia 2010/10/08 cGMP-Specific Sildenafil citrate Revatio IV Phosphodiesterase Type 5 2010/08/31 Inhibitor Silodosin Rapaflo Alpha-1 adrenergic blocker 2012/03/05 Siltuximab Sylvant Immunosuppressive agent 2015/01/02 Siponimod Mayzent Immunomodulatory agent 2020/04/24 Sitagliptin Januvia Hypoglycemic agent 2012/11/20 Sitagliptin and Janumet Hypoglycemic agent 2009/09/24 metformin Endothelin receptor Sitaxsentan Thelin antagonist Sodium zirconium Lokelma Potassium binder 2019/10/17 cyclosilicate Sofosbuvir + Epclusa Antiviral agent 2016/07/11 velpatasvir Sofosbuvir + Antiviral agent for treatment velpatasvir + Vosevi of chronic hepatitis C 2017/09/18 voxilaprevir infection Sonidegib Odomzo Antineoplastic agent 2020/06/11 Stiripentol Diacomit Antiepileptic 2014/12/21 Sumatriptan + Serotonin receptor agonist + Suvexx 2020/07/24 naproxen NSAID Suvorexant Belsomra Hypnotic 2019/04/16 cGMP-specific Tadalafil Adcirca phosphodiesterase type 5 2009/11/25 inhibitor Selective stabilizer of Tafamidis Vyndaqel 2020/04/07 transthyretin - cardiac drug Tamsulosin + Alpha-1 blocker + 5-Alpha Jalyn 2012/02/03 dutasteride reductase inhibitor Tapentadol Nucynta CR Opioid analgesic 2011/03/01 Date Marketed in Common Generic Name Classification Canada Trade Name(s) (yyyy/mm/dd) Tapentadol Nucynta IR Opioid analgesic 2012/03 Tedizolid Sivextro Oxazolidinone antibiotic 2015/10/08 Telaprevir Incivek Antiviral agent 2011/10/06 Angiotensin II antagonists Telmisartan + Twynsta and calcium channel 2011/08/03 amlodipine blockers Tryptophan hydroxylase Telotristat ethyl Xermelo 2018/10/12 inhibitor Sodium/hydrogen exchanger Tenapanor Ibsrela 2020/11/23 inhibitor Protein kinase inibitor Tepotinib Tepmetko (antineoplastic agent) Teriflunomide Aubagio Immunomodulator agent 2013/11/15 Teriparatide Osnuvo Bone formation agent 2020/10/27 Testosterone Natesto Androgen 2016/05/06 Pontocaine Tetracaine (spinal Local anesthetic anesthesia) Thalidomide Thalomid Immunomodulatory agent 2010/08/06 Hormone replacement Tibolone Tibella 2020/07/29 therapy Ticagrelor Brilinta Platelet aggregation inhibitor 2011/06/01 Tiotropium + Inspiolto Bronchodilator combination - 2015/05/29 olodaterol Respimat LAMA plus LABA « first? previous ? 4 5 6 7 8 9 10 11 12 next ? last » © 2017 BC Drug and Poison Information Centre All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the full terms and conditions below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases. Terms and Conditions Source URL (retrieved on 2021-09-26 03:21): http://www.dpic.org/druglisting/everolimus.
Load more

Recommended publications
  • (CHMP) Agenda for the Meeting on 22-25 February 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
    22 February 2021 EMA/CHMP/107904/2021 Human Medicines Division Committee for medicinal products for human use (CHMP) Agenda for the meeting on 22-25 February 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes 22 February 2021, 09:00 – 19:30, room 1C 23 February 2021, 08:30 – 19:30, room 1C 24 February 2021, 08:30 – 19:30, room 1C 25 February 2021, 08:30 – 19:30, room 1C Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
    [Show full text]
  • Efficacy of Second-Line Treatments for Patients with Advanced Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Af
    Journal of Cancer 2021, Vol. 12 1687 Ivyspring International Publisher Journal of Cancer 2021; 12(6): 1687-1697. doi: 10.7150/jca.51845 Research Paper Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis Fei Chen, Naifei Chen, Zheng Lv, Lingyu Li, Jiuwei Cui Cancer Center, the First Hospital of Jilin University, Changchun, China. Corresponding author: Jiuwei Cui, E-mail: [email protected]; ORCID: 0000-0001-6496-7550. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.08.11; Accepted: 2020.12.13; Published: 2021.01.18 Abstract Purpose: Different second-line treatments of patients with trastuzumab-resistant human epidermal growth factor receptor 2 (HER2) positive breast cancer were examined in randomized controlled trials (RCTs). A network meta-analysis is helpful to evaluate the comparative survival benefits of different options. Methods: We performed a bayesian network meta-analysis using R-4.0.0 software and fixed consistency model to compare the progression free survival (PFS) and overall survival (OS) benefits of different second-line regimens. Results: 13 RCTs (19 publications, 4313 patients) remained for qualitative synthesis and 12 RCTs (17 publications, 4022 patients) were deemed eligible for network meta-analysis. For PFS, we divided network analysis into two parts owing to insufficient connections among treatments. The first part involved 8 treatments in 9 studies and we referred it as PFS (#1).
    [Show full text]
  • SGO-2020-Annual-Meet
    Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer Abstracts for Oral Presentation Scientific Plenary I: Shaping the Future with Innovative Clinical Trials: A Clearer Vision Ahead in Gynecologic Cancer 1 - Scientific Plenary Sentinel lymph node biopsy versus lymphadenectomy for high-grade endometrial cancer staging (SENTOR trial): A prospective multicenter cohort study M.C. Cusimanoa, D. Vicusb, K. Pulmanc, M.Q. Bernardinid, S. Laframboised, T. Mayd, G. Bouchard-Fortierd, L. Hogend, L.T. Gienb, A.L. Covensb, R. Kupetse, B.A. Clarkea, M. Cesaric, M. Rouzbahmand, J. Mirkovicb, G. Turashvilid, M. Magantid, A. Ziad, G.E.V. Ened and S.E. Fergusond. aUniversity of Toronto, Toronto, ON, Canada, bSunnybrook Odette Cancer Centre, Toronto, ON, Canada, cTrillium Health Partners, Credit Valley Hospital/University of Toronto, Mississauga, ON, Canada, dPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, eSunnybrook Cancer Centre/University of Toronto, Toronto, ON, Canada Objective: It is unclear whether sentinel lymph node biopsy (SLNB) can replace complete lymphadenectomy in women with high-grade endometrial cancer (EC). We performed a prospective multicenter cohort study (the SENTOR trial) to evaluate the performance characteristics of SLNB using indocyanine green (ICG) in stage I high-grade EC (ClinicalTrials.gov ID: NCT01886066). Method: Patients with clinical stage I grade 2 endometrioid or high-grade EC (grade 3 endometrioid, serous, clear cell, carcinosarcoma, undifferentiated, or mixed tumors) undergoing laparoscopic or robotic surgery at 3 cancer centers in Toronto, Canada, were prospectively recruited for SLNB with ICG. After SLNB, high-grade EC patients underwent pelvic and paraaortic lymphadenectomy (PLND/PALND), and grade 2 endometrioid EC patients underwent PLND only.
    [Show full text]
  • Votubia, INN-Everolimus
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Votubia 2.5 mg tablets Votubia 5 mg tablets Votubia 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Votubia 2.5 mg tablets Each tablet contains 2.5 mg everolimus. Excipient with known effect Each tablet contains 74 mg lactose. Votubia 5 mg tablets Each tablet contains 5 mg everolimus. Excipient with known effect Each tablet contains 149 mg lactose. Votubia 10 mg tablets Each tablet contains 10 mg everolimus. Excipient with known effect Each tablet contains 297 mg lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. Votubia 2.5 mg tablets White to slightly yellow, elongated tablets of approximately 10.1 mm in length and 4.1 mm in width, with a bevelled edge and no score, engraved with “LCL” on one side and “NVR” on the other. Votubia 5 mg tablets White to slightly yellow, elongated tablets of approximately 12.1 mm in length and 4.9 mm in width, with a bevelled edge and no score, engraved with “5” on one side and “NVR” on the other. Votubia 10 mg tablets White to slightly yellow, elongated tablets of approximately 15.1 mm in length and 6.0 mm in width, with a bevelled edge and no score, engraved with “UHE” on one side and “NVR” on the other. 2 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with TSC who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.
    [Show full text]
  • Osteonecrosis of the Jaw Associated with Ziv-Aflibercept
    Case Report Osteonecrosis of the jaw associated with ziv-aflibercept Hani Mawardi1,2,3, Peter Enzinger4, Nadine McCleary5, Reshma Manon6, Alessandro Villa1,2, Nathaniel Treister1,2, Sook-Bin Woo1,2 1Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital, Boston, MA, USA; 2Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA; 3Department of Oral Medicine, Infection and Immunity, King Abdulaziz University, Jeddah, Saudi Arabia; 4Center for Esophageal and Gastric Cancer, 5Deptment of Medical Oncology, Dana Farber Cancer institute, Boston, MA, USA; 6Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA Correspondence to: Hani Mawardi. Associate Surgeon, Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital, Boston, MA, USA. Email: [email protected]. Abstract: Medication-related osteonecrosis of the jaw (MRONJ) has been associated with medications that include bisphosphonates (BPs), denosumab, bevacizumab and sunitinib. Ziv-aflibercept is a recombinant human vascular endothelial growth factor (VEGF) receptor which has been used to treat patients with various advanced solid tumors. We report three patients without a history of the use of medications known to cause MRONJ presenting with jaw osteonecrosis typical for MRONJ following therapy with ziv- aflibercept. All patients had metastatic gastrointestinal cancer treated with ziv-aflibercept and were evaluated for MRONJ because of exposed bone in the oral cavity. None of the patients had received antiresorptive therapies or any other medication known to cause MRONJ, and none had received radiation therapy to the jaws. Patients were aged 43, 51, 63 and all were males. Patients received 7, 16 and 23 cycles of ziv-aflibercept treatment and developed necrotic bone.
    [Show full text]
  • Everolimus Eluting Coronary Stent System
    Everolimus Eluting Coronary Stent System Patient Information Guide Table of Contents Coronary Artery Disease (CAD) ........................5 Your Drug-Eluting Stent Procedure ................19 Your Heart ........................................................5 How Do I Prepare for My Procedure? ...........19 What is CAD? ..................................................5 Your Drug-Eluting Stent Placement What are the Symptoms of CAD? ...................5 Procedure ......................................................19 What are the Risk Factors of CAD? ................6 Immediately after Procedure .........................22 How Can My Doctor Tell if I Have CAD? .........7 Take All Medications as Instructed ................22 Follow-up Care ..............................................23 Your Treatment Options .....................................8 Keep Your ID Card Handy .............................23 Surgery .............................................................9 Angioplasty ......................................................9 Preventing CAD ................................................24 Coronary Artery Stents ..................................10 Frequently Asked Questions ...........................25 Drug-Eluting Stents (DES) ...............................11 Definition of Medical Terms ............................26 XIENCE Family of Coronary Stents ................12 Contraindications ...........................................13 Potential Adverse Events Associated with the XIENCE Family of Coronary Stents ..........13
    [Show full text]
  • Phase I Study of Everolimus, Cetuximab and Irinotecan As Second-Line Therapy in Metastatic Colorectal Cancer
    ANTICANCER RESEARCH 35: 1567-1574 (2015) Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line Therapy in Metastatic Colorectal Cancer J. RANDOLPH HECHT1, TONY R. REID2, CHRISTOPHER R. GARRETT3, J. THADDEUS BECK4, SHELDON J. DAVIDSON5, MARY J. MACKENZIE6, ULRIKE BRANDT7, SYED RIZVI8 and SUNIL SHARMA9 1David Geffen School of Medicine at University of California, Los Angeles, Santa Monica, CA, U.S.A.; 2University of California at San Diego, Moores Cancer Center, La Jolla, CA, U.S.A.; 3University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.; 4Highlands Oncology Group, Fayetteville, AR, U.S.A.; 5Leavey Cancer Center, Northridge, CA, U.S.A.; 6London Regional Cancer Centre, London, ON, Canada; 7Novartis Pharma AG, Postfach, Basel, Switzerland; 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, U.S.A.; 9Huntsman Cancer Institute, Salt Lake City, UT, U.S.A. Abstract. Aim: To evaluate feasible doses of weekly Modern chemotherapy agents such as fluoropyrimidines, everolimus and irinotecan given with cetuximab for pre - oxaliplatin, and irinotecan have significantly improved the viously treated metastatic colorectal cancer (mCRC). survival of patients with metastatic colorectal cancer Patients and Methods: Adults with mCRC that progressed (mCRC) (1, 2). Adding antibodies to vascular endothelial after 5-fluorouracil or capecitabine-plus-oxaliplatin were growth factor (VEGF) and epidermal growth factor receptor treated using a sequential dose escalation scheme. Dosing (EGFR) to standard cytotoxic chemotherapy extends decisions were based on the probability of experiencing a survival in patients with mCRC (3, 4). The EGFR dose-limiting toxicity (DLT) during the first two 21-day antibodies cetuximab and panitumumab, given as treatment cycles.
    [Show full text]
  • February 2021 EPS Pipeline Report
    Pipeline Report February 2021 Pipeline Report February 2021 © 2021 Envolve. All rights reserved. Page 1 This quarterly at-a-glance publication is developed by our Clinical Pharmacy Drug Information team to increase your understanding of the drug pipeline, Table of Contents ensuring you’re equipped with insights to prepare for shifts in pharmacy benefit management. In this issue, you’ll learn more about key themes and notable drugs referenced in the following points. COVID-19 1 > Veklury is currently the only agent that is FDA-approved for the treatment of COVID-19. Three additional therapeutics and two vaccines have been granted Emergency Use Authorization (EUA), and at least three more vaccines are Recent Specialty Drug Approvals1 4 expected to receive an EUA in the relatively near future. > The previous quarter noted the approval of several breakthrough therapies for rare or ultra-rare conditions, which previously had no available FDA-approved Recent Non-Specialty Drug Approvals 9 treatments — Zokinvy for Hutchinson-Gilford progeria syndrome and progeroid laminopathies, Oxlumo for primary hyperoxaluria type 1, and Imcivree for genetically mediated obesity. Upcoming Specialty Products 10 > Other notable approvals include: Lupkynis — the first oral therapy approved for lupus nephritis; Orladeyo — the first oral therapy approved as prophylaxis of hereditary angioedema attacks;Cabenuva – the first long-acting injectable antiretroviral therapy intended as maintenance treatment of HIV; and Breyanzi — Upcoming Non-Specialty Products 18 the
    [Show full text]
  • Emetogenic Potential of Antineoplastic Agents
    EMETOGENIC POTENTIAL OF ANTINEOPLASTIC AGENTS High Risk (>90% frequency without antiemetics) • AC combination: Doxorubicin or Epirubicin (Ellence) ϩ • Doxorubicin IV: >60mg/m 2 Cyclophosphamide (Cytoxan) IV • Epirubicin (Ellence) IV: >90mg/m 2 • Altretamine (HMM, Hexalen) oral • Ifosfamide (Ifex) IV: Ն2g/m 2 per dose • Carmustine (BCNU, BiCNU) IV: Ͼ250mg/m 2 • Mechlorethamine (Mustargen) IV • Cisplatin (CDDP) IV • Procarbazine (Matulane) oral • Cyclophosphamide (CTX, Cytoxan) IV: Ͼ1,500mg/m 2 • Streptozocin (Zanosar) IV • Dacarbazine (DTIC, DTIC-Dome) IV Moderate Risk (30–90% frequency without antiemetics) 2 2 • Aldesleukin (IL-2, Proleukin) IV: Ͼ12–15 million IU/m • Doxorubicin IV: Յ60mg/m 2 2 • Amifostine (Ethyol) IV: Ͼ300mg/m • Epirubicin (Ellence) IV: Յ90mg/m • Arsenic trioxide (As2 O3 , Trisenox) IV • Estramustine (Emcyt) oral • Azacitidine (Vidaza) IV • Etoposide (VP-16) oral • Bendamustine (Treanda) IV • Idarubicin (Idamycin) IV • Busulfan (Busulfex) IV ; oral: Ͼ4mg/day • Ifosfamide (Ifex) IV: Ͻ2g/m 2 • Carboplatin IV • Interferon alpha (IFN-alfa, Intron A) IV: Ն10 million IU/m 2 • Carmustine (BCNU, BiCNU) IV: Յ250mg/m 2 • Irinotecan (CPT-11, Camptosar) IV • Clofarabine (Clolar) IV • Lomustine (CCNU, CeeNU) oral • Cyclophosphamide (CTX, Cytoxan) IV: Յ1,500mg/m 2 • Melphalan (L-PAM, Alkeran) IV • Cyclophosphamide (CTX) oral Ն100mg/m 2 /day • Methotrexate (MTX) IV: Ն250mg/m 2 • Cytarabine (ARA-C) IV: Ͼ200mg/m 2 • Oxaliplatin (Eloxatin) IV • Dactinomycin (Cosmegen) IV • Temozolomide (Temodar) IV; oral Ͼ75mg/m 2 /day • Daunorubicin
    [Show full text]
  • Study Protocol
    ~ GILEAU CLINICAL STUDY PROTOCOL Study Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects with Active Rheumatoid Althritis on Background Therapy with Methotrexate Sponsor: Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 INDNumber: IND 123903 EudraCT Number: 2016-001496-75 Clinical Trials.gov Identifier: TBD Indication: Rheumatoid Arthritis Protocol ID: GS-US-379-1582 Gilead Clinical Name: TomDoan Program Manager: Telephone: PPD Gilead Medical Name: Franziska Matzkies Monitor: Telephone: PPD Fax: PPD Mobile: PPD Protocol Version/Date: Original: 08 April 2016 Amendment 1: 27 Jlme 2016 CONFIDENTIALITY STATEMENT The infonnation contained in this document, pruticularly unpublished data, is the prope1ty or under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent Ethics Committee. The infmmation is only to be used by you in connection with authorized clinical studies of the investigational dmg described in the protocol. You will not disclose any of the infmmation to others without written authorization from Gilead Sciences, Inc., except to the extent necessa1y to obtain inf01med consent from those persons to whom the dmg may be administered. GS-9876 Protocol GS-US-379-1582 Gilead Sciences, Inc. Amendment 1 TABLE OF CONTENTS TABLE OF CONTENTS ..............................................................................................................................................2
    [Show full text]
  • Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment Yang Liu1,2,3,4, Srilakshmi Pandeswara2, Vinh Dao1,2, Alvaro Padron 2, Justin M
    Published OnlineFirst October 13, 2016; DOI: 10.1158/0008-5472.CAN-16-1140 Cancer Therapeutics, Targets, and Chemical Biology Research Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment Yang Liu1,2,3,4, Srilakshmi Pandeswara2, Vinh Dao1,2, Alvaro Padron 2, Justin M. Drerup1, Shunhua Lao2, Aijie Liu2, Vincent Hurez2, and Tyler J. Curiel1,2,3 Abstract mTOR drives tumor growth but also supports T-cell function, memory T cells in EL4 challenge, but without clinical benefit. LD rendering the applications of mTOR inhibitors complex especially rapamycin significantly enhanced DD treatment efficacy, but DD in T-cell malignancies. Here, we studied the effects of the mTOR plus LD rapamycin treatment effects were independent of anti- inhibitor rapamycin in mouse EL4 T-cell lymphoma. Typical tumor immunity. Instead, rapamycin upregulated EL4 IL2 recep- pharmacologic rapamycin (1–8 mg/kg) significantly reduced tor in vitro and in vivo, facilitating direct DD tumor cell killing. tumor burden via direct suppression of tumor cell proliferation LD rapamycin augmented DD efficacy against B16 melanoma and improved survival in EL4 challenge independent of antitu- and a human B-cell lymphoma, but not against human Jurkat mor immunity. Denileukin diftitox (DD)–mediated depletion T-cell lymphoma or ID8agg ovarian cancer cells. Treatment of regulatory T cells significantly slowed EL4 growth in vivo in a effects correlated with IL2R expression, but mechanisms in T-cell–dependent fashion. However, typical rapamycin inhibited some tumors were not fully defined. Overall, our data define T-cell activation and tumor infiltration in vivo and failed to boost a distinct, biphasic mechanisms of action of mTOR inhibition DD treatment effects.
    [Show full text]
  • Trastuzumab Deruxtecan for the Treatment of HER2-Positive Advanced Gastric Cancer: a Clinical… 569
    Gastric Cancer (2021) 24:567–576 https://doi.org/10.1007/s10120-021-01164-x REVIEW ARTICLE Trastuzumab deruxtecan for the treatment of HER2‑positive advanced gastric cancer: a clinical perspective Masahiko Aoki1 · Satoru Iwasa1 · Narikazu Boku1 Received: 2 December 2020 / Accepted: 22 January 2021 / Published online: 1 March 2021 © The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2021 Abstract Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is a subtype for which new drugs and specifc treat- ment strategies should be developed. Trastuzumab deruxtecan (T-DXd) is a novel HER2-targeted antibody–drug conjugate containing topoisomerase I inhibitor as a payload. In the randomized phase 2 study (DESTINY-Gastric01) for HER2-positive advanced gastric or gastroesophageal junction cancer (AGC), patients treated with T-DXd showed a signifcantly higher response rate compared with the chemotherapy of physician’s choice, associated with remarkably prolonged progression- free and overall survival. T-DXd also exhibits anti-tumor activity to HER2-negative tumor cells close to HER2-positive cells (so-called bystander killing efect). T-DXd was efective even for HER2-low expressing breast and gastric cancer in several clinical studies. Taking advantage of these strong points and synergism with other cytotoxic, molecular-targeted and immunological agents, it is expected that T-DXd will bring further progression in treatment both for strongly and weakly HER2 positive AGC in various treatment settings
    [Show full text]